Publication: Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19.
dc.contributor.author | Ramos-Rincon, Jose Manuel | |
dc.contributor.author | Perez-Belmonte, Luis M | |
dc.contributor.author | Carrasco-Sanchez, Francisco Javier | |
dc.contributor.author | Jansen-Chaparro, Sergio | |
dc.contributor.author | De-Sousa-Baena, Mercedes | |
dc.contributor.author | Bueno-Fonseca, Jose | |
dc.contributor.author | Perez-Aguilar, Maria | |
dc.contributor.author | Arevalo-Cañas, Coral | |
dc.contributor.author | Bacete-Cebrian, Marta | |
dc.contributor.author | Mendez-Bailon, Manuel | |
dc.contributor.author | Fiteni-Mera, Isabel | |
dc.contributor.author | Gonzalez-Garcia, Andres | |
dc.contributor.author | Navarro-Romero, Francisco | |
dc.contributor.author | Tuñon-de-Almeida, Carlota | |
dc.contributor.author | Muñiz-Nicolas, Gemma | |
dc.contributor.author | Gonzalez-Noya, Amara | |
dc.contributor.author | Hernandez-Milian, Almudena | |
dc.contributor.author | Garcia-Garcia, Gema Maria | |
dc.contributor.author | Alcala-Pedrajas, Jose Nicolas | |
dc.contributor.author | Herrero-Garcia, Virginia | |
dc.contributor.author | Corral-Gudino, Luis | |
dc.contributor.author | Comas Casanova, Pere | |
dc.contributor.author | Meijide-Miguez, Hector | |
dc.contributor.author | Casas-Rojo, Jose Manuel | |
dc.contributor.author | Gomez-Huelgas, Ricardo | |
dc.contributor.group | SEMI-COVID-19 Network | |
dc.date.accessioned | 2023-02-09T11:38:24Z | |
dc.date.available | 2023-02-09T11:38:24Z | |
dc.date.issued | 2021-05-04 | |
dc.description.abstract | The effects of cardiometabolic drugs on the prognosis of diabetic patients with COVID-19, especially very old patients, are not well known. This work was aimed to analyze the association between preadmission cardiometabolic therapy (antidiabetic, antiaggregant, antihypertensive, and lipid-lowering drugs) and in-hospital mortality among patients ≥80 years with type 2 diabetes mellitus (T2DM) hospitalized for COVID-19. We conducted a nationwide, multicenter, observational study in patients ≥80 years with T2DM hospitalized for COVID-19 between March 1 and May 29, 2020. The primary outcome measure was in-hospital mortality. A multivariate logistic regression analysis was performed to assess the association between preadmission cardiometabolic therapy and in-hospital mortality. Of the 2 763 patients ≥80 years old hospitalized due to COVID-19, 790 (28.6%) had T2DM. Of these patients, 385 (48.7%) died during admission. On the multivariate analysis, the use of dipeptidyl peptidase-4 inhibitors (adjusted odds ratio [AOR] 0.502, 95% confidence interval [CI]: 0.309-0.815, p = .005) and angiotensin receptor blockers (AOR 0.454, 95% CI: 0.274-0.759, p = .003) were independent protectors against in-hospital mortality, whereas the use of acetylsalicylic acid was associated with higher in-hospital mortality (AOR 1.761, 95% CI: 1.092-2.842, p = .020). Other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins showed neutral association with in-hospital mortality. We found important differences between cardiometabolic drugs and in-hospital mortality in older patients with T2DM hospitalized for COVID-19. Preadmission treatment with dipeptidyl peptidase-4 inhibitors and angiotensin receptor blockers could reduce in-hospital mortality; other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins seem to have a neutral effect; and acetylsalicylic acid could be associated with excess mortality. | |
dc.description.version | Si | |
dc.identifier.citation | Ramos-Rincón JM, Pérez-Belmonte LM, Carrasco-Sánchez FJ, Jansen-Chaparro S, De-Sousa-Baena M, Bueno-Fonseca J, et al. Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19. J Gerontol A Biol Sci Med Sci. 2021 Jul 13;76(8):e102-e109 | |
dc.identifier.doi | 10.1093/gerona/glab124 | |
dc.identifier.essn | 1758-535X | |
dc.identifier.pmc | PMC8135901 | |
dc.identifier.pmid | 33945610 | |
dc.identifier.pubmedURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135901/pdf | |
dc.identifier.unpaywallURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135901 | |
dc.identifier.uri | http://hdl.handle.net/10668/17741 | |
dc.issue.number | 8 | |
dc.journal.title | The journals of gerontology. Series A, Biological sciences and medical sciences | |
dc.journal.titleabbreviation | J Gerontol A Biol Sci Med Sci | |
dc.language.iso | en | |
dc.organization | Área Sanitaria Norte de Córdoba | |
dc.organization | Hospital Universitario Juan Ramón Jiménez | |
dc.organization | Hospital Costa del Sol | |
dc.organization | Hospital Universitario Regional de Málaga | |
dc.organization | Instituto de Investigación Biomédica de Málaga-IBIMA | |
dc.organization | AGS - Norte de Córdoba | |
dc.page.number | 8 | |
dc.provenance | Realizada la curación de contenido 14/03/2025 | |
dc.publisher | Oxford University Press | |
dc.pubmedtype | Journal Article | |
dc.pubmedtype | Multicenter Study | |
dc.pubmedtype | Observational Study | |
dc.relation.publisherversion | https://academic.oup.com/biomedgerontology/article-lookup/doi/10.1093/gerona/glab124 | |
dc.rights.accessRights | Restricted Access | |
dc.subject | Age ≥ 80 | |
dc.subject | Cardiometabolic therapy | |
dc.subject | Coronavirus disease-2019 | |
dc.subject | Mortality | |
dc.subject | Type 2 diabetes | |
dc.subject | Área Sanitaria Norte de Córdoba | |
dc.subject.decs | Mortalidad Hospitalaria | |
dc.subject.decs | Hipoglucemiantes | |
dc.subject.decs | Aspirina | |
dc.subject.decs | Inhibidores de la Enzima Convertidora de Angiotensina | |
dc.subject.decs | Inhibidores de Hidroximetilglutaril-CoA Reductasas | |
dc.subject.decs | Antagonistas de Receptores de Angiotensina | |
dc.subject.mesh | Aged, 80 and over | |
dc.subject.mesh | Angiotensin Receptor Antagonists | |
dc.subject.mesh | COVID-19 | |
dc.subject.mesh | Cardiovascular Diseases | |
dc.subject.mesh | Diabetes Mellitus, Type 2 | |
dc.subject.mesh | Dipeptidyl-Peptidase IV Inhibitors | |
dc.subject.mesh | Female | |
dc.subject.mesh | Hospital Mortality | |
dc.subject.mesh | Hospitalization | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Hypoglycemic Agents | |
dc.subject.mesh | Male | |
dc.subject.mesh | SARS-CoV-2 | |
dc.title | Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19. | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 76 | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- RISalud_Accesorestringido.pdf
- Size:
- 93.39 KB
- Format:
- Adobe Portable Document Format